Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM.

Endocr Relat Cancer. 2010 Jun 25;17(3):623-36. doi: 10.1677/ERC-09-0318. Print 2010 Sep.

PMID:
20385747
2.

Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.

Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, Ames MM.

Pancreas. 2013 Apr;42(3):411-21. doi: 10.1097/MPA.0b013e31826cb243.

3.

A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.

Martins AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gúrpide J, de Alava E.

Cancer Res. 2008 Aug 1;68(15):6260-70. doi: 10.1158/0008-5472.CAN-07-3074.

4.

EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases.

Lopes LF, Bacchi CE.

Mod Pathol. 2007 Sep;20(9):990-4. Epub 2007 Jul 20.

5.

Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate.

Wang X, Jones TD, Zhang S, Eble JN, Bostwick DG, Qian J, Lopez-Beltran A, Montironi R, Harris JJ, Cheng L.

Mod Pathol. 2007 Feb;20(2):175-82. Epub 2006 Dec 22.

6.

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.

Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Mar;6(3):1123-32.

7.

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.

Rydén L, Jirström K, Haglund M, Stål O, Fernö M.

Breast Cancer Res Treat. 2010 Apr;120(2):491-8. doi: 10.1007/s10549-010-0758-6. Epub 2010 Feb 5.

PMID:
20135347
8.

Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors.

Li CF, Huang WW, Wu JM, Yu SC, Hu TH, Uen YH, Tian YF, Lin CN, Lu D, Fang FM, Huang HY.

Clin Cancer Res. 2008 Dec 1;14(23):7822-31. doi: 10.1158/1078-0432.CCR-08-1369.

10.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

12.

Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer.

Ueda S, Hatsuse K, Tsuda H, Ogata S, Kawarabayashi N, Takigawa T, Einama T, Morita D, Fukatsu K, Sugiura Y, Matsubara O, Mochizuki H.

Mod Pathol. 2006 Jun;19(6):788-96.

14.

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.

Terry J, Lubieniecka JM, Kwan W, Liu S, Nielsen TO.

Clin Cancer Res. 2005 Aug 1;11(15):5631-8.

15.

Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.

Schwock J, Pham NA, Cao MP, Hedley DW.

Cancer Chemother Pharmacol. 2008 Apr;61(4):669-81. Epub 2007 Jun 20.

PMID:
17579866
17.

Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.

Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G, Papotti M.

Endocr Relat Cancer. 2010 Oct 29;17(4):977-87. doi: 10.1677/ERC-10-0157. Print 2010 Dec.

18.

Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.

Le Tourneau C, Vidal L, Siu LL.

Drug Resist Updat. 2008 Jun;11(3):99-109. doi: 10.1016/j.drup.2008.04.001. Epub 2008 Jun 2. Review.

PMID:
18515176
19.

Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.

Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.

J Exp Ther Oncol. 2008;7(3):183-93.

PMID:
19066127
20.

Supplemental Content

Support Center